Reginald Segar, MD
Family Medicine · Eunice, LANPI 1720057417
Payments from drug & device makers
Across 209 payments — averaging $14.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$652
- Novo Nordisk$626
- GSK$497
- AbbVie$332
- Pfizer$321
- Lilly USA, LLC$158
- plus $504 from 12 others
What the payments were for
- Food & beverage$3,089100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $652 |
| Novo Nordisk | 45 | $626 |
| GSK | 36 | $497 |
| AbbVie(2 entities) | 27 | $332 |
| Pfizer | 14 | $321 |
| Lilly USA, LLC | 11 | $158 |
| Novartis | 8 | $125 |
| Amarin Pharma, Inc. | 4 | $64 |
| Bayer | 3 | $50 |
| Teva Pharmaceuticals USA, Inc. | 4 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Boehringer Ingelheim | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Shire North American Group Inc | 2 | $30 |
| Avanir Pharmaceuticals, Inc. | 2 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EUCRISA$127
How this compares
$3,089 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 141 | $95,397 |
| OzempicSemaglutide | 85 | $91,456 |
| JardianceEmpagliflozin | 123 | $85,726 |
| EliquisApixaban | 118 | $68,312 |
| LinzessLinaclotide | 83 | $45,658 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $33,084 |
| TrulicityDulaglutide | 36 | $32,526 |
| MounjaroTirzepatide | 25 | $31,268 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 22 | $24,109 |
| EntrestoSacubitril/Valsartan | 25 | $16,524 |
| JanuviaSitagliptin Phosphate | 23 | $15,825 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $15,273 |
| InvokanaCanagliflozin | 15 | $11,112 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $7,899 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 365 | $7,661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $652 | $98,287153 claims |
| Novo NordiskOzempic | $626 | $91,45685 claims |
| Boehringer IngelheimJardiance | $37 | $85,726123 claims |
| PfizerEliquis | $321 | $68,312118 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $158 | $63,79561 claims |
| AbbVieLinzess, Namzaric, Lumigan | $332 | $55,522109 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $497 | $48,35791 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $30 | $24,10922 claims |
| MerckJanuvia, Janumet | $15 | $23,72537 claims |
| NovartisEntresto | $125 | $16,52425 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $46 | $3,81311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Eunice
- David WareEunice$29K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.